NCT03618654View on ClinicalTrials.gov

Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

November 20, 2021

Study Completion Date

December 7, 2022

Conditions
Head and Neck Squamous Cell CarcinomaOral Cavity Squamous Cell CarcinomaOropharyngeal Squamous Cell Carcinoma
Interventions
DRUG

Metformin

Given PO

BIOLOGICAL

Durvalumab

Given IV

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

All Listed Sponsors
lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT03618654 - Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter